The 5-year survival rate and median survival time of ESCC patients with low Beclin1 expression were 10.5% and 22 ± 1.56 months, respectively, which were significantly shorter than those of the patients with high Beclin1 expression (48.3% and 53 ± 1.57) (p = 0.0001), as presented in Table 5 and Figure 3C. This evidence concerns the gene BECN1 and esophageal squamous cell carcinoma.